{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T07:05:30Z","timestamp":1781679930770,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82151310"],"award-info":[{"award-number":["82151310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation","award":["L246018"],"award-info":[{"award-number":["L246018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11060-024-04929-3","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T08:21:42Z","timestamp":1737274902000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas"],"prefix":"10.1007","volume":"172","author":[{"given":"Xuzhe","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaokang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2683-2580","authenticated-orcid":false,"given":"Dabiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"4929_CR1","doi-asserted-by":"publisher","first-page":"vi1","DOI":"10.1093\/neuonc\/noae145","volume":"26","author":"M Price","year":"2024","unstructured":"Price M, Ballard C, Benedetti J et al (2024) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017\u20132021. Neuro Oncol 26:vi1\u2013vi85. https:\/\/doi.org\/10.1093\/neuonc\/noae145","journal-title":"Neuro Oncol"},{"key":"4929_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"4929_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.clon.2015.04.008","volume":"27","author":"MB Pinkham","year":"2015","unstructured":"Pinkham MB, Telford N, Whitfield GA et al (2015) FISHing tips: what every clinician should know about 1p19q analysis in gliomas using fluorescence in situ hybridisation. Clin Oncol 27:445\u2013453. https:\/\/doi.org\/10.1016\/j.clon.2015.04.008","journal-title":"Clin Oncol"},{"key":"4929_CR4","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1097\/01.jnen.0000235122.98052.8f","volume":"65","author":"CA Griffin","year":"2006","unstructured":"Griffin CA, Burger P, Morsberger L et al (2006) Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 65:988\u2013994. https:\/\/doi.org\/10.1097\/01.jnen.0000235122.98052.8f","journal-title":"J Neuropathol Exp Neurol"},{"key":"4929_CR5","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"4929_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/jnci\/90.19.1473","volume":"90","author":"JG Cairncross","year":"1998","unstructured":"Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473\u20131479. https:\/\/doi.org\/10.1093\/jnci\/90.19.1473","journal-title":"J Natl Cancer Inst"},{"key":"4929_CR7","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.ejca.2006.05.021","volume":"42","author":"MCM Kouwenhoven","year":"2006","unstructured":"Kouwenhoven MCM, Kros JM, French PJ et al (2006) 1p\/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499\u20132503. https:\/\/doi.org\/10.1016\/j.ejca.2006.05.021","journal-title":"Eur J Cancer"},{"key":"4929_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/neuonc\/noac198","volume":"25","author":"QT Ostrom","year":"2023","unstructured":"Ostrom QT, Shoaf ML, Cioffi G et al (2023) National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25:799\u2013807. https:\/\/doi.org\/10.1093\/neuonc\/noac198","journal-title":"Neuro Oncol"},{"key":"4929_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","volume":"18","author":"M Weller","year":"2021","unstructured":"Weller M, van den Bent M, Preusser M et al (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170\u2013186. https:\/\/doi.org\/10.1038\/s41571-020-00447-z","journal-title":"Nat Rev Clin Oncol"},{"key":"4929_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1093\/neuonc\/not235","volume":"16","author":"G Reyes-Botero","year":"2014","unstructured":"Reyes-Botero G, Dehais C, Idbaih A et al (2014) Contrast enhancement in 1p\/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16:662\u2013670. https:\/\/doi.org\/10.1093\/neuonc\/not235","journal-title":"Neuro Oncol"},{"key":"4929_CR11","doi-asserted-by":"publisher","first-page":"e12929","DOI":"10.1111\/bpa.12929","volume":"31","author":"A Roux","year":"2021","unstructured":"Roux A, Tran S, Edjlali M et al (2021) Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis. Brain Pathol 31:e12929. https:\/\/doi.org\/10.1111\/bpa.12929","journal-title":"Brain Pathol"},{"key":"4929_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s11060-018-2872-y","volume":"139","author":"J-M Hempel","year":"2018","unstructured":"Hempel J-M, Brendle C, Bender B et al (2018) Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. J Neurooncol 139:373\u2013381. https:\/\/doi.org\/10.1007\/s11060-018-2872-y","journal-title":"J Neurooncol"},{"key":"4929_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejca.2018.10.019","volume":"107","author":"B Suchorska","year":"2019","unstructured":"Suchorska B, Sch\u00fcller U, Biczok A et al (2019) Contrast enhancement is a prognostic factor in IDH1\/2 mutant, but not in wild-type WHO grade II\/III glioma as confirmed by machine learning. Eur J Cancer 107:15\u201327. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.019","journal-title":"Eur J Cancer"},{"key":"4929_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11060-019-03183-2","volume":"143","author":"F Castet","year":"2019","unstructured":"Castet F, Alanya E, Vidal N et al (2019) Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. J Neurooncol 143:515\u2013523. https:\/\/doi.org\/10.1007\/s11060-019-03183-2","journal-title":"J Neurooncol"},{"key":"4929_CR15","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00701-021-05103-8","volume":"164","author":"A Krigers","year":"2022","unstructured":"Krigers A, Demetz M, Grams AE et al (2022) The diagnostic value of contrast enhancement on MRI in diffuse and anaplastic gliomas. Acta Neurochir (Wien) 164:2035\u20132040. https:\/\/doi.org\/10.1007\/s00701-021-05103-8","journal-title":"Acta Neurochir (Wien)"},{"key":"4929_CR16","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1215\/15228517-2008-066","volume":"11","author":"J Pallud","year":"2009","unstructured":"Pallud J, Capelle L, Taillandier L et al (2009) Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. Neuro Oncol 11:176\u2013182. https:\/\/doi.org\/10.1215\/15228517-2008-066","journal-title":"Neuro Oncol"},{"key":"4929_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.3174\/ajnr.A2895","volume":"33","author":"L Khalid","year":"2012","unstructured":"Khalid L, Carone M, Dumrongpisutikul N et al (2012) Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol 33:852\u2013857. https:\/\/doi.org\/10.3174\/ajnr.A2895","journal-title":"AJNR Am J Neuroradiol"},{"key":"4929_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s11060-014-1526-y","volume":"120","author":"H Jiang","year":"2014","unstructured":"Jiang H, Ren X, Zhang Z et al (2014) Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors. J Neurooncol 120:131\u2013138. https:\/\/doi.org\/10.1007\/s11060-014-1526-y","journal-title":"J Neurooncol"},{"key":"4929_CR19","unstructured":"Board WC of TE Central Nervous System Tumours"},{"key":"4929_CR20","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3171\/2018.12.JNS182775","volume":"132","author":"H Jiang","year":"2020","unstructured":"Jiang H, Cui Y, Liu X et al (2020) Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region. J Neurosurg 132:998\u20131005. https:\/\/doi.org\/10.3171\/2018.12.JNS182775","journal-title":"J Neurosurg"},{"key":"4929_CR21","doi-asserted-by":"publisher","first-page":"20162","DOI":"10.1038\/s41598-020-77228-2","volume":"10","author":"D-W Shin","year":"2020","unstructured":"Shin D-W, Lee S, Song SW et al (2020) Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases. Sci Rep 10:20162. https:\/\/doi.org\/10.1038\/s41598-020-77228-2","journal-title":"Sci Rep"},{"key":"4929_CR22","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1200\/JCO.23.01059","volume":"41","author":"PY Wen","year":"2023","unstructured":"Wen PY, van den Bent M, Youssef G et al (2023) RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol 41:5187\u20135199. https:\/\/doi.org\/10.1200\/JCO.23.01059","journal-title":"J Clin Oncol"},{"key":"4929_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10014-018-0321-4","volume":"35","author":"T Yamauchi","year":"2018","unstructured":"Yamauchi T, Ohno M, Matsushita Y et al (2018) Radiological characteristics based on isocitrate dehydrogenase mutations and 1p\/19q codeletion in grade II and III gliomas. Brain Tumor Pathol 35:148\u2013158. https:\/\/doi.org\/10.1007\/s10014-018-0321-4","journal-title":"Brain Tumor Pathol"},{"key":"4929_CR24","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/neuonc\/now256","volume":"19","author":"H Zhou","year":"2017","unstructured":"Zhou H, Valli\u00e8res M, Bai HX et al (2017) MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro Oncol 19:862\u2013870. https:\/\/doi.org\/10.1093\/neuonc\/now256","journal-title":"Neuro Oncol"},{"issue":"Suppl 4","key":"4929_CR25","doi-asserted-by":"publisher","first-page":"iv55","DOI":"10.1093\/neuonc\/nos199","volume":"14","author":"R Rud\u00e0","year":"2012","unstructured":"Rud\u00e0 R, Bello L, Duffau H, Soffietti R (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14(Suppl 4):iv55\u2013iv64. https:\/\/doi.org\/10.1093\/neuonc\/nos199","journal-title":"Neuro Oncol"},{"key":"4929_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/brain\/awt345","volume":"137","author":"J Pallud","year":"2014","unstructured":"Pallud J, Audureau E, Blonski M et al (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449\u2013462. https:\/\/doi.org\/10.1093\/brain\/awt345","journal-title":"Brain"},{"key":"4929_CR27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/brain\/awl317","volume":"130","author":"S Ivens","year":"2007","unstructured":"Ivens S, Kaufer D, Flores LP et al (2007) TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 130:535\u2013547. https:\/\/doi.org\/10.1093\/brain\/awl317","journal-title":"Brain"},{"key":"4929_CR28","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.08.025","volume":"105","author":"MC Tom","year":"2019","unstructured":"Tom MC, Park DYJ, Yang K et al (2019) Malignant transformation of molecularly classified adult low-grade glioma. Int J Radiat Oncol Biol Phys 105:1106\u20131112. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4929_CR29","doi-asserted-by":"publisher","first-page":"vdab101","DOI":"10.1093\/noajnl\/vdab101","volume":"3","author":"Z Satar","year":"2021","unstructured":"Satar Z, Hotton G, Samandouras G (2021) Systematic review-Time to malignant transformation in low-grade gliomas: Predicting a catastrophic event with clinical, neuroimaging, and molecular markers. Neurooncol Adv 3:vdab101. https:\/\/doi.org\/10.1093\/noajnl\/vdab101","journal-title":"Neurooncol Adv"},{"key":"4929_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-017-2576-8","volume":"135","author":"Y Li","year":"2017","unstructured":"Li Y, Qian Z, Xu K et al (2017) Radiomic features predict Ki-67 expression level and survival in lower grade gliomas. J Neurooncol 135:317\u2013324. https:\/\/doi.org\/10.1007\/s11060-017-2576-8","journal-title":"J Neurooncol"},{"key":"4929_CR31","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/neuonc\/not092","volume":"15","author":"X Ren","year":"2013","unstructured":"Ren X, Jiang H, Cui X et al (2013) Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p\/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases. Neuro Oncol 15:1244\u20131250. https:\/\/doi.org\/10.1093\/neuonc\/not092","journal-title":"Neuro Oncol"},{"key":"4929_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/neuonc\/noz098","volume":"21","author":"H Chen","year":"2019","unstructured":"Chen H, Thomas C, Munoz FA et al (2019) Polysomy is associated with poor outcome in 1p\/19q codeleted oligodendroglial tumors. Neuro Oncol 21:1164\u20131174. https:\/\/doi.org\/10.1093\/neuonc\/noz098","journal-title":"Neuro Oncol"},{"key":"4929_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/embor.2012.55","volume":"13","author":"AJ Holland","year":"2012","unstructured":"Holland AJ, Cleveland DW (2012) Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep 13:501\u2013514. https:\/\/doi.org\/10.1038\/embor.2012.55","journal-title":"EMBO Rep"},{"key":"4929_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/neuonc\/noac193","volume":"25","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Young JS, Dono A et al (2023) Prognostic validation of a new classification system for extent of resection in glioblastoma: a report of the RANO resect group. Neuro Oncol 25:940\u2013954. https:\/\/doi.org\/10.1093\/neuonc\/noac193","journal-title":"Neuro Oncol"},{"key":"4929_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11060-024-04747-7","volume":"169","author":"A Roux","year":"2024","unstructured":"Roux A, Elia A, Hudelist B et al (2024) Prognostic significance of MRI contrast enhancement in newly diagnosed glioblastoma, IDH-wildtype according to WHO 2021 classification. J Neurooncol 169:445\u2013455. https:\/\/doi.org\/10.1007\/s11060-024-04747-7","journal-title":"J Neurooncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04929-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04929-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T15:19:57Z","timestamp":1743175197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04929-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4929"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04929-3","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for this study was waived by the Review Board of Beijing Tiantan Hospital due to the observational retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants and their families included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images in all Figures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}